



**PRESS RELEASE**

February 19, 2026  
Gothenburg

## Management change at XVIVO – CFO transitions to new role

**XVIVO Perfusion AB (publ) today announces that the company's CFO, Kristoffer Nordström, has been appointed Senior Vice President Corporate Strategy & Business Development, effective April 1, 2026. He will continue to be a member of XVIVO's Executive Management Team.**

Senior Vice President Corporate Strategy & Business Development is a newly established global role with a particular focus on the U.S. market. In the U.S., XVIVO has several important upcoming launches within heart, kidney, and liver, and this initiative is part of the company's continued efforts to strengthen its U.S. organization. In addition to his focus on corporate strategy and business development, Kristoffer Nordström will also lead the U.S. service organization.

"During his five years as CFO at XVIVO, Kristoffer Nordström has played a key role in the company's financial and strategic development. As we strengthen our commercial presence and invest for growth in the U.S., we see clear value in leveraging Kristoffer's experience and expertise in a more business-focused role," says Christoffer Rosenblad, CEO of XVIVO.

The recruitment process for a new CFO has been initiated. Kristoffer Nordström will remain in his role as CFO until a successor has assumed the position.

19 February 2026  
Molndal, Sweden  
Christoffer Rosenblad, CEO  
XVIVO Perfusion AB (publ)

### **For further information, please contact:**

---

Christoffer Rosenblad, CEO, +46 73 519 21 59, e-mail: [christoffer.rosenblad@xvivogroup.com](mailto:christoffer.rosenblad@xvivogroup.com)  
Kristoffer Nordström, CFO, +46 73 519 21 64, e-mail: [kristoffer.nordstrom@xvivogroup.com](mailto:kristoffer.nordstrom@xvivogroup.com)

### **About Us**

---

Founded in 1998, XVIVO is the only medical technology company dedicated to extending the life of all major organs - so transplant teams around the world can save more lives. Our solutions allow leading clinicians and researchers to push the boundaries of transplantation medicine. XVIVO is headquartered in Gothenburg, Sweden, and has offices and research sites on two continents. The company is listed on Nasdaq Stockholm under the ticker symbol XVIVO. More information can be found on the website [www.xvivogroup.com](http://www.xvivogroup.com).

## Attachments

---

**Management change at XVIVO – CFO transitions to new role**